The clinical use of structural MRI in Alzheimer disease

By Giovanni B. Frisoni, Nick C Fox, Clifford R. Jack Jr., Philip Scheltens, P. Thompson. Nature Reviews Neurology, 2010

2,140 citations recorded by the source corpus.

Structural imaging based on magnetic resonance is an integral part of the clinical assessment of patients with suspected Alzheimer dementia. Prospective data on the natural history of change in structural markers from preclinical to overt stages of Alzheimer disease are radically changing how the disease is conceptualized, and will influence its future diagnosis and treatment. Atrophy of medial temporal structures is now considered to be a valid diagnostic marker at the mild cognitive impairment stage. Structural imaging is also included in diagnostic criteria for the most prevalent non-Alzheimer dementias, reflecting its value in differential diagnosis. In addition, rates of whole-brain and hippocampal atrophy are sensitive markers of neurodegeneration, and are increasingly used as outcome measures in trials of potentially disease-modifying therapies. Large multicenter studies are currently investigating the value of other imaging and nonimaging markers as adjuncts to clinical assessment in diagnosis and monitoring of progression. The utility of structural imaging and other markers will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment.

Subfields: Physiology, Psychiatry and Mental health, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a5728230c995efc6ff76399a89a77b3baa930284

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Brain imaging in Alzheimer disease. (2012, background): “Nonetheless, hippocampal atrophy is a feature of DLB and VaD, and in frontotemporal dementia (FTD) can be more severe anteriorly than in AD (Barber et al. 2000; Chan et al. 2001; McKeith et al. 2005; Burton et al. 2009).”
Hierarchical Fully Convolutional Network for Joint Atrophy Localization and Alzheimer’s Disease Diagnosis using Structural MRI (2018, background): “Structural magnetic resonance imaging (sMRI) can non-invasively capture profound brain changes induced by the atrophic process [3], based on which various computer-aided diagnosis (CAD) approaches [4], [5], [6] have been proposed for the early diagnosis of AD as well as its pro-”
Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer's Disease: A Systematic Review (2017, methodology): “…diﬀusion tensor imaging (DTI), single photon emission tomography (SPECT), and positron emission tomography (PET) have been widely and successfully applied in the study of MCI and AD (Greicius et al., 2004; Matsuda, 2007; Fripp et al., 2008; Frisoni et al., 2010; Acosta-Cabronero and Nestor, 2014).”
Alzheimer's disease (2018, background): “The presence of focal symmetrical medial temporal atrophy has predictive value for AD [50].”
Modeling disease progression via multi-task learning (2013, neutral): “…cognitive scores and imagingmarkers based onMRI such as graymatter volumes, density and loss (Apostolova et al., 2006; Chetelat and Baron, 2003; Frisoni et al., 2002, 2010; Stonnington et al., 2010), shape of ventricles (Ferrarini et al., 2008; Thompson et al., 2004) and hippocampal (Thompson…”
A multi-task learning formulation for predicting disease progression (2011, methodology): “imaging markers based on MRI such as gray matter volumes, density and loss [3, 8, 15, 16, 33], shape of ventricles [14, 34] and hippocampal [34] by correlating these features with baseline MMSE scores.”
A review on neuroimaging‐based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages (2017, positive): “It has been suggested that this inevitable atrophy can be a valuable marker of neurodegeneration (Frisoni et al., 2010), as measured with structural magnetic resonance imaging (sMRI).”